Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Vyvanse Capsules CII for the Treatment of ADHD in Adolescents

By Pharmaceutical Processing | November 15, 2010

Shire plc today announced that the FDA has approved the prescription
medication Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment
of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to
17. The approval is based on study data demonstrating that Vyvanse improved ADHD
symptoms compared to placebo in adolescents with ADHD. Vyvanse is also
indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

“This adolescent indication for Vyvanse is good news
for kids in this age group diagnosed with ADHD and their caregivers as it
offers an additional treatment option to help them manage their symptoms,”
said Mike Yasick, Senior Vice President of Shire’s ADHD Business. “The approval
of Vyvanse for children and adults – and now for adolescents – underscores
Shire’s commitment to helping ADHD patients and their families.”

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE